Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Related Posts
Moghanaki D, Cameron EA, Garon EB. Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2025 Jun[...]
Bardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta[...]
Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A.[...]